Twist Bioscience Corporation Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross
Twist Bioscience Corporation (TWST) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross of 0 shares for the 6-month period ending 2023-03-31, per its 10-Q filed 2023-05-08.
Discontinued › Shareholders' Equity
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross · last filed 2023-06-05
- Twist Bioscience Corporation share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2023-03-31 was 0.00 shares.
- Twist Bioscience Corporation share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2022-12-31 was 0.00 shares.
- Twist Bioscience Corporation share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2022-09-30 was 0.00 shares.
- Twist Bioscience Corporation share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2019-09-30 was 66.95K shares.
- Twist Bioscience Corporation share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2022 was 223.00K shares.
- Twist Bioscience Corporation share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2019 was 1.69M shares, a 77.19% increase from fiscal 2018.
- Twist Bioscience Corporation share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2018 was 951.31K shares, a 10.99% increase from fiscal 2017.
- Twist Bioscience Corporation share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2017 was 857.08K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 12 month |
|---|---|---|---|---|
| 2023-03-31 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-05-08 | 0.00 shares 10-Q · filed 2023-05-08 | 0.00 shares derived: sum of 3 quarters · filed 2023-06-05 | |
| 2022-12-31 | 0.00 shares 10-Q · filed 2023-02-07 | 0.00 shares derived: sum of 2 quarters · filed 2023-06-05 | ||
| 2022-09-30 | 0.00 shares derived: 10-K/A 12 month − 10-Q 9 month · filed 2023-06-05 | 223.00K shares 10-K/A · filed 2023-06-05 | ||
| 2022-06-30 | 223.00K shares 10-Q · filed 2022-08-08 | |||
| 2019-09-30 | 66.95K shares derived: 10-K 12 month − 10-Q 9 month · filed 2019-12-13 | 173.78K shares derived: sum of 2 quarters · filed 2019-12-13 | 647.09K shares derived: sum of 3 quarters · filed 2019-12-13 | 1.69M shares 10-K · filed 2019-12-13 |
| 2019-06-30 | 106.83K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2019-08-09 | 580.14K shares derived: sum of 2 quarters · filed 2019-08-09 | 1.62M shares 10-Q · filed 2019-08-09 | |
| 2019-03-31 | 473.31K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2019-05-02 | 1.51M shares 10-Q · filed 2019-05-02 | ||
| 2018-12-31 | 1.04M shares 10-Q · filed 2019-02-11 | |||
| 2018-09-30 | 951.31K shares 10-K · filed 2019-12-13 | |||
| 2017-09-30 | 857.08K shares 10-K · filed 2019-12-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |